Human papillomavirus vaccines for cervical cancer.
The association of carcinoma of the uterine cervix with human papillomavirus indicates that vaccine strategies which target the virus could be useful in the control of disease progression. Recent advances have centered on directing the immune response to prevention of infection, to virus-infected (but nontransformed) cells and to virally transformed cells, with favourable results.
Tindle
R W
RW
Papillomavirus Research Unit, University of Queensland, Princess Alexandra Hospital, Boisbane, Australia. Rtindle@gpo.pa.uq.edu.au
D000818:Animals; D000957:Antigens, Viral, Tumor / Q000235:genetics; D019496:Cancer Vaccines / Q000494:pharmacology*; D002472:Cell Transformation, Viral; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D027383:Papillomaviridae / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity; D053918:Papillomavirus Vaccines; D002583:Uterine Cervical Neoplasms / Q000209:etiology / Q000517:prevention & control / Q000628:therapy*; D014765:Viral Vaccines / Q000494:pharmacology*; D014779:Virus Replication / Q000276:immunology
D000957:Antigens, Viral, Tumor; D019496:Cancer Vaccines; D053918:Papillomavirus Vaccines; D014765:Viral Vaccines